Why the study?
Does amlodipine plus benazepril reduce major fatal and non-fatal cardiovascular endpoints compared to benazepril plus hydrochlorothiazide in hypertensive patients at high cardiovascular risk?
Does amlodipine plus benazepril reduce major fatal and non-fatal cardiovascular endpoints compared to benazepril plus hydrochlorothiazide in hypertensive patients at high cardiovascular risk?
The ACCOMPLISH trial successfully enrolled a highly comorbid hypertensive population, with 60% having diabetes and a mean BMI in the obese range, reflecting secular trends in cardiovascular risk.
Answers are grounded in this paper and cite their sources.
ACCOMPLISH results apply to obese, diabetic hypertensives at high CV risk; extends prior trials by reflecting current comorbidity patterns.
ACCOMPLISH is the first trial designed to compare the effects on major fatal and non-fatal cardiovascular endpoints of two forms of antihypertensive combination therapy: benazepril plus hydrochlorothiazide and amlodipine plus benazepril in hypertensive patients at high cardiovascular risk. Enrollment for this trial is now complete and this report describes the clinical characteristics of the study cohort. Patients with hypertension and a previous history of cardiovascular events, strokes or diabetes mellitus were randomized to double-blind treatment with either of the two combination regimens. The data in this report detail the clinical history and demographic characteristics in patients immediately prior to randomization to study drugs. A total of 11,454 patients were randomized. Mean age (+/-SD) was 68.4+/-6.9 years, 60% were men, and 1360 (12%) were African American. Mean body mass index (BMI) was 31.0+/-6.3 kg/m(2). At study entry, 46% of patients had a history of acute coronary syndromes, coronary artery bypass grafts or percutaneous coronary interventions; 13% had a history of stroke. A history of diabetes mellitus was reported in 6928 (60%) of patients. Mean blood pressure at baseline (on prior hypertension therapy) was 145.4/80.0 mmHg; only 38% of patients had a BP less than 140/90 mmHg. Overall, 97% of patients had received previous antihypertensive treatment (74% on at least two drugs); 53% were on oral diabetes therapy or insulin, 68% on anti-lipid therapy and 63% on anti-platelet agents. In summary, the ACCOMPLISH trial has recruited hypertensive patients at high risk of cardiovascular morbidity and mortality. It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease.
No takes yet. Share an insight, caveat, or question.
Weber et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: